003220.KS
Daewon Pharmaceutical Co., Ltd. [003220.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
003220.KS Stock Summary
Top 10 Correlated ETFs
003220.KS
Top 10 Correlated Stocks
003220.KS
In the News
003220.KS Financial details
Company Rating
Strong Buy
Market Cap
300.98B
Income
23.92B
Revenue
526.95B
Book val./share
12558.89
Cash/share
1416.78
Dividend
-
Dividend %
-
Employees
1.13K
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
12.34
Forward P/E
8.29
PEG
-5.04
P/S
0.64
P/B
1.21
P/C
9.9
P/FCF
12.88
Quick Ratio
-
Current Ratio
1.58
Debt / Equity
0.55
LT Debt / Equity
0.13
-
-
EPS (TTM)
1.14K
EPS next Y
1692
EPS next Q
435.12
EPS this Y
-24.5%
EPS next Y
48.41%
EPS next 5Y
-
EPS last 5Y
-2.06%
Revenue last 5Y
10.64%
Revenue Q/Q
9.21%
EPS Q/Q
-86.41%
-
-
-
-
SMA20
-4.82%
SMA50
-2.87%
SMA100
-11.21%
Inst Own
-
Inst Trans
-
ROA
5%
ROE
10%
ROC
0.09%
Gross Margin
49%
Oper. Margin
6%
Profit Margin
5%
Payout
-
Shs Outstand
21.2M
Shs Float
11.41M
-
-
-
-
Target Price
-
52W Range
13530.0-19490.0
52W High
-28.01%
52W Low
+3.7%
RSI
26.51
Rel Volume
0.23
Avg Volume
89.66K
Volume
20.92K
Perf Week
-4.17%
Perf Month
-4.49%
Perf Quarter
-9.01%
Perf Half Y
-11.59%
-
-
-
-
Beta
0.487
-
-
Volatility
145.7%, 393.16%
Prev Close
-1.2%
Price
14030
Change
-0.28%
003220.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 14.73K | 14.45K | 16.69K | 22.63K | 25.12K | |
| Net income per share | 1.27K | 826.31 | 329.36 | 1.51K | 1.14K | |
| Operating cash flow per share | 1.44K | 1.17K | 1.06K | 1.58K | 2.34K | |
| Free cash flow per share | -263.36 | 429.42 | 504.57 | 943.39 | 1.29K | |
| Cash per share | 871.43 | 492.81 | 2.58K | 2.22K | 1.43K | |
| Book value per share | 9.5K | 10.02K | 10.33K | 11.86K | 12.69K | |
| Tangible book value per share | 8.52K | 8.86K | 8.39K | 9.86K | 10.62K | |
| Share holders equity per share | 9.5K | 10.02K | 10.33K | 11.86K | 12.69K | |
| Interest debt per share | 2.38K | 2.51K | 5.94K | 5.68K | 7.14K | |
| Market cap | 335.01B | 382.95B | 343.01B | 394.61B | 333.19B | |
| Enterprise value | 373.17B | 424.99B | 425.28B | 484.12B | 449.25B | |
| P/E ratio | 12.28 | 21.71 | 49.08 | 12.35 | 13.93 | |
| Price to sales ratio | 1.05 | 1.24 | 0.97 | 0.82 | 0.63 | |
| POCF ratio | 10.82 | 15.35 | 15.3 | 11.84 | 6.8 | |
| PFCF ratio | -58.97 | 41.77 | 32.04 | 19.77 | 12.31 | |
| P/B Ratio | 1.63 | 1.79 | 1.56 | 1.57 | 1.25 | |
| PTB ratio | 1.63 | 1.79 | 1.56 | 1.57 | 1.25 | |
| EV to sales | 1.17 | 1.38 | 1.2 | 1.01 | 0.85 | |
| Enterprise value over EBITDA | 7.81 | 10.36 | 10.73 | 7.42 | 9.02 | |
| EV to operating cash flow | 12.05 | 17.03 | 18.97 | 14.53 | 9.17 | |
| EV to free cash flow | -65.69 | 46.36 | 39.72 | 24.25 | 16.6 | |
| Earnings yield | 0.08 | 0.05 | 0.02 | 0.08 | 0.07 | |
| Free cash flow yield | -0.02 | 0.02 | 0.03 | 0.05 | 0.08 | |
| Debt to equity | 0.25 | 0.25 | 0.57 | 0.46 | 0.55 | |
| Debt to assets | 0.16 | 0.16 | 0.29 | 0.26 | 0.29 | |
| Net debt to EBITDA | 0.8 | 1.02 | 2.08 | 1.37 | 2.33 | |
| Current ratio | 1.97 | 2.09 | 1.77 | 1.62 | 1.15 | |
| Interest coverage | 130.72 | 20.38 | 9.35 | 11.68 | 6.99 | |
| Income quality | 1.15 | 1.45 | 3.39 | 1.09 | 2.05 | |
| Dividend Yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | |
| Payout ratio | 0.18 | 0.29 | 0.45 | 0.13 | 0.31 | |
| Sales general and administrative to revenue | 0.07 | 0.07 | 0.08 | 0.09 | 0.06 | |
| Research and developement to revenue | 0.03 | 0.04 | 0.07 | 0.04 | 0.03 | |
| Intangibles to total assets | 0.06 | 0.07 | 0.09 | 0.09 | 0.08 | |
| Capex to operating cash flow | -1.18 | -0.63 | -0.52 | -0.4 | -0.45 | |
| Capex to revenue | -0.12 | -0.05 | -0.03 | -0.03 | -0.04 | |
| Capex to depreciation | -3.1 | -1.01 | -0.66 | -0.69 | -1.25 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 16.44K | 13.65K | 8.75K | 20.07K | 18.04K | |
| ROIC | 0.1 | 0.07 | 0.02 | 0.09 | 0.07 | |
| Return on tangible assets | 0.09 | 0.06 | 0.02 | 0.08 | 0.05 | |
| Graham Net | -1.86K | -2.22K | -3.73K | -2.83K | -5.06K | |
| Working capital | 59.81B | 61.26B | 78.3B | 79.14B | 26.6B | |
| Tangible asset value | 183.75B | 189.1B | 177.96B | 208.69B | 222.79B | |
| Net current asset value | -1.77B | -5.17B | -30.8B | 2.5B | -34.44B | |
| Invested capital | 0.25 | 0.25 | 0.57 | 0.46 | 0.55 | |
| Average receivables | 48.32B | 47.25B | 50B | 62.85B | 71.29B | |
| Average payables | 7.9B | 9.81B | 13.95B | 18.4B | 20.25B | |
| Average inventory | 48.23B | 57.98B | 66.74B | 80.77B | 98.46B | |
| Days sales outstanding | 58.58 | 51.45 | 58.24 | 52.73 | 50.84 | |
| Days payables outstanding | 23.69 | 27.36 | 35.37 | 29.67 | 27.99 | |
| Days of inventory on hand | 138.28 | 163.34 | 143.14 | 139.14 | 140.63 | |
| Receivables turnover | 6.23 | 7.09 | 6.27 | 6.92 | 7.18 | |
| Payables turnover | 15.41 | 13.34 | 10.32 | 12.3 | 13.04 | |
| Inventory turnover | 2.64 | 2.23 | 2.55 | 2.62 | 2.6 | |
| ROE | 0.13 | 0.08 | 0.03 | 0.13 | 0.09 | |
| Capex per share | -1.7K | -739.36 | -551.71 | -631.66 | -1.05K |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 5.84K | 5.92K | 6.34K | 6.15K | 6.65K | |
| Net income per share | 141.4 | 459.31 | 385.3 | 260.15 | 35.36 | |
| Operating cash flow per share | -125.11 | 475.59 | 831.02 | 23.81 | 1.09K | |
| Free cash flow per share | -228.9 | 305.12 | 697.04 | -268.65 | 642.59 | |
| Cash per share | 2.24K | 2.25K | 2.2K | 1.58K | 1.42K | |
| Book value per share | 11.97K | 12.07K | 12.44K | 12.69K | 12.56K | |
| Tangible book value per share | 9.95K | 10K | 10.32K | 10.46K | 10.51K | |
| Share holders equity per share | 11.97K | 12.07K | 12.44K | 12.69K | 12.56K | |
| Interest debt per share | 5.6K | 5.49K | 5.5K | 5.88K | 6.9K | |
| Market cap | 391.1B | 301.77B | 298.41B | 342.03B | 336.59B | |
| Enterprise value | 480.61B | 408.7B | 396.78B | 452.41B | 452.66B | |
| P/E ratio | 32.97 | 7.83 | 9.23 | 15.67 | 112.28 | |
| Price to sales ratio | 3.19 | 2.43 | 2.24 | 2.65 | 2.39 | |
| POCF ratio | -149.07 | 30.26 | 17.12 | 685.04 | 14.61 | |
| PFCF ratio | -81.48 | 47.16 | 20.42 | -60.71 | 24.71 | |
| P/B Ratio | 1.56 | 1.19 | 1.14 | 1.29 | 1.26 | |
| PTB ratio | 1.56 | 1.19 | 1.14 | 1.29 | 1.26 | |
| EV to sales | 3.92 | 3.29 | 2.98 | 3.51 | 3.21 | |
| Enterprise value over EBITDA | 48.91 | 28.66 | 6.06 | 7.54 | 37.35 | |
| EV to operating cash flow | -183.18 | 40.98 | 22.77 | 906.12 | 19.65 | |
| EV to free cash flow | -100.12 | 63.87 | 27.14 | -80.31 | 33.23 | |
| Earnings yield | 0.01 | 0.03 | 0.03 | 0.02 | 0 | |
| Free cash flow yield | -0.01 | 0.02 | 0.05 | -0.02 | 0.04 | |
| Debt to equity | 0.46 | 0.45 | 0.44 | 0.46 | 0.55 | |
| Debt to assets | 0.26 | 0.25 | 0.25 | 0.26 | 0.29 | |
| Net debt to EBITDA | 9.11 | 7.5 | 1.5 | 1.84 | 9.58 | |
| Current ratio | 1.62 | 1.59 | 1.64 | 1.58 | 1.15 | |
| Interest coverage | 4.97 | 8.06 | 8.58 | 5.85 | 5.49 | |
| Income quality | -0.97 | 1.05 | 2.18 | 0.09 | 30.74 | |
| Dividend Yield | 0 | 0 | 0.02 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0.91 | 0 | 0 | |
| Sales general and administrative to revenue | 0.17 | 0.05 | 0.42 | 0.41 | 0.06 | |
| Research and developement to revenue | 0.05 | 0.03 | 0.03 | 0.03 | 0.04 | |
| Intangibles to total assets | 0.09 | 0.09 | 0.09 | 0.09 | 0.08 | |
| Capex to operating cash flow | 0.83 | -0.36 | -0.16 | -12.28 | -0.41 | |
| Capex to revenue | -0.02 | -0.03 | -0.02 | -0.05 | -0.07 | |
| Capex to depreciation | -0.47 | -0.75 | -0.67 | -1.43 | -1.66 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 6.17K | 11.17K | 10.39K | 8.62K | 3.16K | |
| ROIC | 0.02 | 0.03 | 0.02 | 0.02 | 0 | |
| Return on tangible assets | 0.01 | 0.02 | 0.02 | 0.01 | 0 | |
| Graham Net | -2.86K | -2.92K | -2.81K | -3.09K | -5.01K | |
| Working capital | 79.14B | 77.15B | 79.29B | 81B | 26.6B | |
| Tangible asset value | 208.69B | 209.68B | 216.35B | 219.42B | 222.79B | |
| Net current asset value | 2.5B | 2.18B | 3.03B | 5.8B | -34.44B | |
| Invested capital | 0.46 | 0.45 | 0.44 | 0.46 | 0.55 | |
| Average receivables | 68.15B | 67.19B | 64.87B | 78.62B | 83.06B | |
| Average payables | 20.33B | 19.3B | 19.55B | 22.96B | 23.37B | |
| Average inventory | 87.39B | 93.79B | 94.46B | 94.02B | 99.97B | |
| Days sales outstanding | 50.82 | 47.29 | 43.66 | 64.69 | 46.9 | |
| Days payables outstanding | 28.71 | 27.2 | 26.76 | 33.71 | 26.34 | |
| Days of inventory on hand | 134.68 | 136.92 | 124.17 | 123.79 | 132.37 | |
| Receivables turnover | 1.77 | 1.9 | 2.06 | 1.39 | 1.92 | |
| Payables turnover | 3.13 | 3.31 | 3.36 | 2.67 | 3.42 | |
| Inventory turnover | 0.67 | 0.66 | 0.72 | 0.73 | 0.68 | |
| ROE | 0.01 | 0.04 | 0.03 | 0.02 | 0 | |
| Capex per share | -103.79 | -170.47 | -133.99 | -292.46 | -444.36 |
003220.KS Frequently Asked Questions
What is Daewon Pharmaceutical Co., Ltd. stock symbol ?
Daewon Pharmaceutical Co., Ltd. is a KR stock and trading under the symbol 003220.KS
What is Daewon Pharmaceutical Co., Ltd. stock quote today ?
Daewon Pharmaceutical Co., Ltd. stock price is $14030 today.
Is Daewon Pharmaceutical Co., Ltd. stock public?
Yes, Daewon Pharmaceutical Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 89.66K
- Market Capitalization 300.98B
- Employee 1.13K
- CEO Mr. Seung-Ryel Baek
- Headquarters Seoul,KR
- IPO Date 2005-09-29
-
Website
https://www.daewonpharm.com 
Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, produces and sells medicine and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis uses. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a therapy for gastritis and duodenal ulcer; and Renamezin Cap, a spherical carbonaceous adsorbent for chronic kidney disease. It also exports its products to approximately 45 countries primarily in Asia, Central and South America, the Middle East, etc. The company was founded in 1958 and is headquartered in Seoul, South Korea.
